1015 related articles for article (PubMed ID: 23021878)
1. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
Gevaert P; Calus L; Van Zele T; Blomme K; De Ruyck N; Bauters W; Hellings P; Brusselle G; De Bacquer D; van Cauwenberge P; Bachert C
J Allergy Clin Immunol; 2013 Jan; 131(1):110-6.e1. PubMed ID: 23021878
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
3. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
4. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
Bardelas J; Figliomeni M; Kianifard F; Meng X
J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P; Omachi TA; Corren J; Mullol J; Han J; Lee SE; Kaufman D; Ligueros-Saylan M; Howard M; Zhu R; Owen R; Wong K; Islam L; Bachert C
J Allergy Clin Immunol; 2020 Sep; 146(3):595-605. PubMed ID: 32524991
[TBL] [Abstract][Full Text] [Related]
6. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab in asthma: an update on recent developments.
Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
[TBL] [Abstract][Full Text] [Related]
12. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
Chervinsky P; Casale T; Townley R; Tripathy I; Hedgecock S; Fowler-Taylor A; Shen H; Fox H
Ann Allergy Asthma Immunol; 2003 Aug; 91(2):160-7. PubMed ID: 12952110
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
15. Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?
Verbruggen K; Van Cauwenberge P; Bachert C
Int Arch Allergy Immunol; 2009; 148(2):87-98. PubMed ID: 18799888
[TBL] [Abstract][Full Text] [Related]
16. Functional endoscopic sinus surgery improved asthma symptoms as well as PEFR and olfaction in patients with nasal polyposis.
Ehnhage A; Olsson P; Kölbeck KG; Skedinger M; Dahlén B; Alenius M; Stjärne P;
Allergy; 2009 May; 64(5):762-9. PubMed ID: 19191775
[TBL] [Abstract][Full Text] [Related]
17. Biologics and the treatment of chronic rhinosinusitis.
Kern RC
J Allergy Clin Immunol; 2013 Jan; 131(1):117-8. PubMed ID: 23265697
[No Abstract] [Full Text] [Related]
18. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
Maselli DJ; Singh H; Diaz J; Peters JI
Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
[TBL] [Abstract][Full Text] [Related]
19. Should clinicians use omalizumab for the treatment of nasal polyps?
Naclerio RM; Baroody FM; Pinto JM
J Allergy Clin Immunol; 2013 Jul; 132(1):247. PubMed ID: 23684073
[No Abstract] [Full Text] [Related]
20. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
